Identification of TLR signaling network

TLR信号网络的识别

基本信息

  • 批准号:
    7273683
  • 负责人:
  • 金额:
    $ 232.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-15 至 2009-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Toll-like receptors play a critical role in the initiation of the innate and adaptive immune responses. Members of the TLR family recognize conserved microbial structures and activate signaling pathways that result in immune responses against microbial infections. All TLRs activate common pathways to induce a core set of stereotyped responses, such as inflammation. However, individual TLRs can also induce immune responses that are tailored to a given microbial infection. The mechanisms and components of these varied responses are poorly understood. Given the importance of TLRs in host defense, dissection of these pathways is key to the rational design of immunomodulators and adjuvants. To address the complexity of the TLR signaling network, it is imperative to put in place technologies enabling systematic examination of the signal transduction. ATTAGENE Inc. has developed a reversible genetic approach that affords screening expression libraries of tens of thousands of cDNAs to identify signaling intermediates. We used this methodology to identify a number of novel components of the pathways that mediate interleukin-1-inducible activation of the transcription factor NF-kB. Our studies indicate that the reversible genetic approach offers a highly versatile tool for a systematic, genome-wide identification of signal transduction. This comprehensive approach does not rely on preconceived notions and it has built-in procedures that eliminate false-positive background. In this study, we will adapt the reversible genetic approach to systematic identification of components of the TLR signaling network. Our objectives are (1) to identify the components of signal transduction that link individual members of the TLR family with activation of the transcription factor NF-kB; (2) to annotate those components as positive/negative and differential/common intermediates; (3) to examine biological functions of the identified mediators in innate immune responses in vitro; and (4) to create knock-out animal models in order to assess the identified mediators as potential targets to modulate the innate and adaptive immune responses to different pathogens, including Listeria monocytogenes and Salmonella typhimurium. Successful implementation of the proposed plan should provide comprehensive knowledge of molecular mechanisms controlling immune responses to pathogens, thus greatly facilitating the development of highly specific immunomodulators and adjuvants.
描述(由申请人提供):toll样受体在先天和适应性免疫反应的启动中起关键作用。TLR家族成员识别保守的微生物结构并激活导致针对微生物感染的免疫应答的信号通路。所有的tlr都激活了共同的通路来诱导一系列核心的刻板反应,比如炎症。然而,单个tlr也可以诱导针对特定微生物感染的免疫反应。人们对这些不同反应的机制和组成部分知之甚少。鉴于tlr在宿主防御中的重要性,解剖这些通路是合理设计免疫调节剂和佐剂的关键。为了解决TLR信号网络的复杂性,必须采用能够系统检查信号转导的技术。ATTAGENE公司开发了一种可逆的遗传方法,可以筛选成千上万的cdna表达文库,以识别信号中间体。我们使用这种方法确定了介导白细胞介素-1诱导的转录因子NF-kB激活的途径的一些新成分。我们的研究表明,可逆遗传方法为系统的全基因组信号转导鉴定提供了一种高度通用的工具。这种全面的办法不依赖于先入为主的观念,它有消除假阳性背景的固有程序。在这项研究中,我们将采用可逆遗传方法来系统地识别TLR信号网络的组成部分。我们的目标是:(1)确定将TLR家族的个体成员与转录因子NF-kB的激活联系起来的信号转导成分;(2)将这些成分标注为正/负中间体和微分/共同中间体;(3)体外检测鉴定出的介质在先天免疫应答中的生物学功能;(4)建立敲除动物模型,以评估鉴定的介质作为潜在靶点来调节对不同病原体的先天和适应性免疫反应,包括单核细胞增生李斯特菌和鼠伤寒沙门菌。该计划的成功实施将提供控制病原体免疫反应的分子机制的全面知识,从而极大地促进高度特异性免疫调节剂和佐剂的开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SERGEI S MAKAROV其他文献

SERGEI S MAKAROV的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SERGEI S MAKAROV', 18)}}的其他基金

Assigning mode of action to phenotypically discovered anticancer leads.
将作用模式分配给表型发现的抗癌先导化合物。
  • 批准号:
    10821103
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
Assessing the polypharmacology of kinase inhibitors by transcription factor activity profiling
通过转录因子活性分析评估激酶抑制剂的多药理学
  • 批准号:
    9909795
  • 财政年份:
    2020
  • 资助金额:
    $ 232.6万
  • 项目类别:
Predicting DILI liability by transcription factor profiling
通过转录因子分析预测 DILI 责任
  • 批准号:
    9750012
  • 财政年份:
    2017
  • 资助金额:
    $ 232.6万
  • 项目类别:
Predicting DILI liability by transcription factor profiling
通过转录因子分析预测 DILI 责任
  • 批准号:
    9409943
  • 财政年份:
    2017
  • 资助金额:
    $ 232.6万
  • 项目类别:
Identification of TLR signaling network
TLR信号网络的识别
  • 批准号:
    6818795
  • 财政年份:
    2004
  • 资助金额:
    $ 232.6万
  • 项目类别:
Identification of TLR signaling network
TLR信号网络的识别
  • 批准号:
    7455738
  • 财政年份:
    2004
  • 资助金额:
    $ 232.6万
  • 项目类别:
Identification of TLR signaling network
TLR信号网络的识别
  • 批准号:
    6921353
  • 财政年份:
    2004
  • 资助金额:
    $ 232.6万
  • 项目类别:
Identification of TLR signaling network
TLR信号网络的识别
  • 批准号:
    7090874
  • 财政年份:
    2004
  • 资助金额:
    $ 232.6万
  • 项目类别:
Novel biosensors for toxicological applications
用于毒理学应用的新型生物传感器
  • 批准号:
    6744401
  • 财政年份:
    2003
  • 资助金额:
    $ 232.6万
  • 项目类别:
Profiling of signal transduction pathways in cancer
癌症信号转导途径的分析
  • 批准号:
    6734153
  • 财政年份:
    2003
  • 资助金额:
    $ 232.6万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 232.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了